Embodiments of the invention provide methods for the transdermal delivery of therapeutic agents for the treatment of addictive cravings e.g., nicotine compounds for the treatment of nicotine cravings from tobacco use. An embodiment of a method for such delivery comprises positioning at least one electrode assembly in electrical communication with a patient's skin. The assembly includes a solution comprising a therapeutic agent which passively diffuses into the skin. A dose of agent is delivered from the assembly into the skin during a first period using a first current having a characteristic e.g., polarity and magnitude, to repel the agent out of the assembly. During a second period, a second current having a characteristic to attract the agent is used to retain the agent in the assembly such that delivery of agent into skin is minimized. A dose of agent may be delivered on demand by an input from the patient.

A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that demonstrates substantial agonist activity at alpha adrenergic receptors and that is selected for peripheral (local) vasoconstriction and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.

The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.

The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.

A transparent or translucent medical active substance patch is provided that includes a matrix of monolayer or multilayer configuration with at least one active substance-containing layer contained therein and a backing layer connected with the matrix. The patch, having been applied to the skin of a first person, has a lightness color value L.sub.1 at a place of the skin covered by the patch which is not less than 50% and not more than 200% of a lightness color value L.sub.2, with L.sub.2 being the lightness value of the region of skin of the same person which surrounds the applied patch, with the same being true of the skin of a second or any other person, provided that for all the persons mentioned, the L.sub.2 of their respective skin is in the range from 5° to 100°, especially in the range from 20° to 90°.

A transparent or translucent medical active substance patch is provided that includes a matrix of monolayer or multilayer configuration with at least one active substance-containing layer contained therein and a backing layer connected with the matrix. The patch, having been applied to the skin of a first person, has a lightness color value L.sub.1 at a place of the skin covered by the patch which is not less than 50% and not more than 200% of a lightness color value L.sub.2, with L.sub.2 being the lightness value of the region of skin of the same person which surrounds the applied patch, with the same being true of the skin of a second or any other person, provided that for all the persons mentioned, the L.sub.2 of their respective skin is in the range from 5° to 100°, especially in the range from 20° to 90°.

A pouched product adapted for release of a releasable component therefrom is provided herein. The pouched product can include a water-permeable fabric pouch formed so as to define a cavity therein, and a composition contained within the cavity of the water-permeable fabric pouch, the composition including one or more releasable components that are released from the composition under mouth conditions and that are capable of movement through the water-permeable fabric pouch. The composition includes nicotine and at least one particulate non-tobacco material. The pouched product also includes at least one capsule contained within the cavity of the water-permeable fabric pouch, the capsule having a capsule wall surrounding an inner payload comprising at least one botanical.

A pouched product adapted for release of a releasable component therefrom is provided herein. The pouched product can include a water-permeable fabric pouch formed so as to define a cavity therein, and a composition contained within the cavity of the water-permeable fabric pouch, the composition including one or more releasable components that are released from the composition under mouth conditions and that are capable of movement through the water-permeable fabric pouch. The composition includes nicotine and at least one particulate non-tobacco material. The pouched product also includes at least one capsule contained within the cavity of the water-permeable fabric pouch, the capsule having a capsule wall surrounding an inner payload comprising at least one botanical.

A cartridge for an aerosol-generating system is provided, the cartridge containing: a first liquid formulation including at least one of water and one or more water-miscible solvents; and a second liquid formulation including one or more water-immiscible solvents having a water solubility at 20° C. of less than or equal to about 100 mg/ml, in which at least one of the first liquid formulation and the second liquid formulation comprises nicotine. An aerosol-generating system is also provided, including the cartridge; and an aerosol-generating device including one or more atomizers configured to generate an aerosol from the first liquid formulation and the second liquid formulation contained in the cartridge.

A cartridge for an aerosol-generating system is provided, the cartridge containing: a first liquid formulation including at least one of water and one or more water-miscible solvents; and a second liquid formulation including one or more water-immiscible solvents having a water solubility at 20° C. of less than or equal to about 100 mg/ml, in which at least one of the first liquid formulation and the second liquid formulation comprises nicotine. An aerosol-generating system is also provided, including the cartridge; and an aerosol-generating device including one or more atomizers configured to generate an aerosol from the first liquid formulation and the second liquid formulation contained in the cartridge.